Filling the need for trusted information on national health issues

U.S. Group Challenges Gilead’s Hepatitis C Drug Patents In 5 Countries

Reuters: Gilead patents on costly hepatitis C drug challenged in five countries
“A U.S. group is trying to block patents in five countries for Gilead Sciences Inc.’s costly hepatitis C drug Sovaldi, in a bid to give almost 60 million afflicted people access to cheaper generic versions. In Argentina, Brazil, China, Russia, and Ukraine, challenges have been filed against Gilead’s patents or patent applications, the New York-based Initiative for Medicines, Access & Knowledge, or I-MAK, said on Wednesday…” (Pierson, 5/20).